Evidence map›Paper›PMID 40968388›Full record

ArticleGenome medicine2025

MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology.

Aleksandra Weronika Nielsen, Hafez Eslami Manoochehri, Hua Zhong, Vandana Panwar, Vipul Jarmale, Jay Jasti, Mehrdad Nourani, Dinesh Rakheja, James Brugarolas, Payal Kapur and 1 more

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aleksandra Weronika NielsenLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hafez Eslami ManoochehriLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hua ZhongLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vandana PanwarDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vipul JarmaleLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jay JastiLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Mehrdad NouraniDepartment of Electrical and Computer Engineering, The University of Texas at Dallas, Richardson, TX, USA.
Dinesh RakhejaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
James BrugarolasKidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Payal KapurDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Payal.Kapur@UTSouthwestern.edu.
Satwik RajaramLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Satwik.Rajaram@UTSouthwestern.edu.

Funding

University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Payal Kapur, Payal Kapur · 2016 to 2026
$24.7M
NCI NIH HHS P50 CA196516The Cancer Prevention and Research Institute of Texas RP210041The Cancer Prevention and Research Institute of Texas RP220294
6 · The paper itself

Abstract

backgroundTumor evolution, driven by the emergence of genetically and epigenetically distinct subclones, enables cancers to adapt to selective pressures and become more aggressive, posing a major challenge in oncology. Multi-regional sequencing has been the primary means of studying tumor evolution and the resultant intra-tumor heterogeneity (ITH), but its high cost, resource-intensiveness, and limited scalability have hindered clinical utility.

methodsHere, we present MorphoITH, a novel framework that aims to infer molecular ITH from routinely collected histopathology slides by quantifying phenotypic diversity. MorphoITH integrates a task-agnostic, self-supervised deep learning similarity measure to capture phenotypic variation across multiple dimensions (cytology, architecture, and microenvironment) along with rigorous methods to eliminate spurious sources of variation.

resultsApplying MorphoITH to clear cell renal cell carcinoma (ccRCC), a disease notably shaped by ITH, we show that it captures clinically significant biological features such as vascular architecture and nuclear grade. MorphoITH also recognizes morphological changes associated with subclonal alterations in key driver genes (BAP1, PBRM1, SETD2). Finally, in a multi-regional sequencing dataset, we find that the morphological trajectories revealed by MorphoITH largely mirror underlying patterns of genetic evolution.

conclusionsMorphoITH provides a scalable and rigorous approach to quantify morphological ITH, serving as a potential proxy for underlying genetic ITH and tumor evolution. By linking histopathology with genomic insights, it lays the foundation for more refined phenotypic profiling in support of precision oncology.

Indexed as

Carcinoma, Renal CellGenetic HeterogeneityKidney NeoplasmsNeoplasmsComputational BiologyHumansPhenotypeArtificial intelligenceCcRCCDeep learningDigital pathologyHistopathologyIntra-tumor heterogeneityKidney cancerTumor evolutionTumor morphology

Identifiers

PMID40968388
PMCPMC12447597

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.